Resultats globals: 10 registres trobats en 0.02 segons.
Articles, 10 registres trobats
Articles 10 registres trobats  
1.
9 p, 500.3 KB Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL / Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Hillmen, Peter (St James Institute of Oncology) ; O'Brien, S. (MD Anderson Cancer Center) ; Barrientos, J.C. (Hofstra Northwell School of Medicine) ; Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ; Coutre, S.E. (Stanford University) ; Tam, C.S. (Peter MacCallum Cancer Centre. St Vincent's Hospital) ; Mulligan, S.P. (Royal North Shore Hospital) ; Jaeger, U. (Medical University of Vienna) ; Barr, P.M. (University of Rochester Cancer Center) ; Furman, R.R. (New York Presbyterian Hospital) ; Kipps, Thomas J (UCSD Moores Cancer Center) ; Cymbalista, F. (Hôpital Avicenne) ; Thornton, P. (Beaumont Hospital (Dublín, Irlanda)) ; Caligaris-Cappio, F. (Universita Vita-Salute San Raffaele) ; Delgado, J. (Hospital Clínic i Provincial de Barcelona) ; Montillo, M. (Niguarda Hospital) ; DeVos, S. (David Geffen School of Medicine at UCLA) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Pagel, J.M. (Swedish Cancer Institute) ; Munir, Talha (St James Institute of Oncology) ; Burger, Jan A (MD Anderson Cancer Center) ; Chung, D. (Pharmacyclics LLC. AbbVie Company) ; Lin, J. (Pharmacyclics LLC. AbbVie Company) ; Gau, L. (Pharmacyclics LLC. AbbVie Company) ; Chang, B. (Pharmacyclics LLC. AbbVie Company) ; Cole, G. (Pharmacyclics LLC. AbbVie Company) ; Hsu, E. (Pharmacyclics LLC. AbbVie Company) ; James, D.F. (Pharmacyclics LLC. AbbVie Company) ; Byrd, J.C. (Ohio State University) ; Universitat Autònoma de Barcelona
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. [...]
2018 - 10.1038/leu.2017.175
Leukemia, Vol. 32 Núm. 1 (january 2018) , p. 83-91  
2.
8 p, 393.1 KB Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry : An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project / Rawstron, Andy C. (St. James's Institute of Oncology) ; Kreuzer, Karl-Anton (Universitätsklinikum Köln) ; Soosapilla, Asha (Laverty Pathology) ; Spacek, Martin (University Hospital) ; Stehlikova, Olga (University Hospital Brno (República Txeca)) ; Gambell, Peter (Peter MacCallum Cancer Centre) ; McIver-Brown, Neil (Royal Bournemouth Hospital) ; Villamor, Neus (Hospital Clínic i Provincial de Barcelona) ; Psarra, Katherina (Evangelismos Hospital) ; Arroz, Maria (C.H.L.O. Hospital S. Francisco Xavier) ; Milani, Raffaella (Ospedale San Raffaele) ; de la Serna, Javier (Hospital 12 de Octubre (Madrid)) ; Cedena, M.Teresa (Hospital 12 de Octubre (Madrid)) ; Jaksic, Ozren (Dubrava University Hospital) ; Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Rigolin, Gian Matteo (St. Anna University Hospital) ; Cuneo, Antonio (St. Anna University Hospital) ; Johansen, Preben (Aalborg Universitet) ; Johnsen, Hans E. (Aalborg Universitet) ; Rosenquist, Richard (Uppsala University) ; Niemann, Carsten Utoft (Copenhagen University Hospital) ; Kern, Wolfgang (MLL Munich Leukemia Laboratory) ; Westerman, David (University Hospital Brno (República Txeca)) ; Trneny, Marek (University Hospital) ; Mulligan, Stephen (Laverty Pathology) ; Doubek, Michael (Masaryk University) ; Pospisilova, Sarka (Masaryk University) ; Hillmen, Peter (St. James's Institute of Oncology) ; Oscier, David (Royal Bournemouth Hospital) ; Hallek, Michael (Universitätsklinikum Köln) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Montserrat, Emili (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. [...]
2018 - 10.1002/cyto.b.21595
Cytometry Part B - Clinical Cytometry, Vol. 94 Núm. 1 (january 2018) , p. 121-128  
3.
9 p, 996.2 KB Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2 / Barr, Paul M. (University of Rochester) ; Robak, Tadeusz (Medical University of Lodz) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ; Bartlett, Nancy L. (Washington University School of Medicine) ; Burger, Jan A. (University of Texas MD Anderson Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Coutre, Steven E (Stanford University School of Medicine) ; Devereux, Stephen (Kings College Hospital) ; Grosicki, Sebastian (School of Public Health. Silesian Medical University) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Li, Jianyong (Jiangsu Province Hospital) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ; Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ; James, Danelle (Pharmacyclics. LLC an AbbVie Company) ; Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. [...]
2018 - 10.3324/haematol.2018.192328
Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510  
4.
19 p, 600.4 KB Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma / Barrientos, Jacqueline C. (Zucker School of Medicine at Hofstra/Northwell) ; O'Brien, Susan (University of California Irvine) ; Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Kay, Neil E. (Mayo Clinic) ; Reddy, Nishitha M. (Vanderbilt-Ingram Cancer Center) ; Coutre, Steven E (Stanford University School of Medicine) ; Tam, Constantine (Peter MacCallum Cancer Centre and St Vincent's Hospital) ; Mulligan, Stephen (Royal North Shore Hospital) ; Jaeger, Ulrich (Medical University of Vienna) ; Devereux, Stephen (King's College Hospital NHS Foundation Trust) ; Pocock, Christopher (East Kent Hospitals University) ; Robak, Tadeusz (Medical University of Lodz) ; Schuster, Stephen J. (Perelman Center for Advanced Medicine) ; Schuh, Anna (University of Oxford) ; Gill, Devinder (Princess Alexandra Hospital) ; Bloor, Adrian (The Christie Clinic) ; Dearden, Claire (The Royal Marsden Hospital) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cull, Gavin (Sir Charles Gardiner Hospital) ; Hamblin, Mike (Colchester Hospital) ; Jones, Jeffrey A. (The Ohio State University Comprehensive Cancer Center) ; Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ; Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ; Suzuki, Samuel (Pharmacyclics LLC. an AbbVie Company) ; Hsu, Emily (Pharmacyclics LLC. an AbbVie Company) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James University Hospital) ; Universitat Autònoma de Barcelona
In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. [...]
2018 - 10.1016/j.clml.2018.08.007
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 12 (december 2018) , p. 803-813.e7  
5.
9 p, 1.3 MB Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies / Robak, Tadeusz (Medical University of Lodz) ; Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Barr, Paul M. (University of Rochester Cancer Center) ; Owen, Carolyn (University of Calgary) ; Bairey, Osnat (Tel Aviv University) ; Hillmen, Peter (St. James's Institute of Oncology) ; Simpson, David (North Shore Hospital) ; Grosicki, Sebastian (Silesian Medical University) ; Devereux, Stephen (King's College Hospital NHS Foundation Trust) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Coutre, Steven E (Stanford University School of Medicine) ; Quach, Hang (St. Vincent's Hospital) ; Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ; Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ; Stevens, Don A. (Norton Cancer Institute) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gill, Devinder S. (Princess Alexandra Hospital) ; Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ; Gribben, John G. (Queen Mary University of London) ; Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ; Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ; Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 - 10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410  
6.
25 p, 1.7 MB Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma / O'Brien, Susan (University of California) ; Hillmen, Peter (St. James University Hospital) ; Coutre, Steven E (Stanford University School of Medicine) ; Barr, Paul M (University of Rochester Cancer Center) ; Fraser, Graeme (McMaster University (Canadà)) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Burger, Jan A. (University of Texas MD Anderson Cancer Center) ; Dilhuydy, Marie-Sarah (Centre Hospitalier Universitaire Hopitaux de Bordeaux) ; Hess, Georg (Universitats Medizin Mainz) ; Moreno Atanasio, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cramer, Paula (University of Cologne) ; Liu, Emily (Pharmacyclics LLC. an AbbVie Company) ; Chang, Stephen (Pharmacyclics LLC. an AbbVie Company) ; Vermeulen, Jessica (Janssen Research & Development) ; Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ; Howes, Angela (Janssen Research & Development) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Patel, Kalpesh (Janssen Pharmaceuticals. Inc) ; Graef, Thorsten (Pharmacyclics LLC. an AbbVie Company) ; Valentino, Rudolph (Pharmacyclics LLC. an AbbVie Company) ; Universitat Autònoma de Barcelona
Ibrutinib, a Bruton's tyrosine kinase inhibitor, has become a standard treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The present pooled safety analysis of 4 randomized controlled studies demonstrated a favorable benefit/risk profile for ibrutinib in patients with CLL/SLL and mantle cell lymphoma. [...]
2018 - 10.1016/j.clml.2018.06.016
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 10 (october 2018) , p. 648-657.e15  
7.
14 p, 1.1 MB Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia / Kipps, Thomas J. (UC San Diego Moores Cancer Center) ; Fraser, Graeme (McMaster University (Canadà)) ; Coutre, Steven E (Stanford University School of Medicine) ; Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Barrientos, Jacqueline C. (Northwell Health Cancer Institute) ; Barr, Paul M. (University of Rochester) ; Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ; O'Brien, Susan M. (University of California) ; Dilhuydy, Marie-Sarah (Hôpital Haut-Lévêque) ; Hillmen, Peter (University of Leeds) ; Jaeger, Ulrich (Medical University of Vienna) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cramer, Paula (University of Cologne) ; Stilgenbauer, Stephan (University of Ulm) ; Chanan-Khan, Asher A. (Mayo Clinic Cancer Center) ; Mahler, Michelle (Janssen Research and Development) ; Salman, Mariya (Janssen Research and Development) ; Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ; Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ; Balasubramanian, Sriram (Janssen Research and Development) ; Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ; Londhe, Anil (Janssen Research and Development) ; Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ; Howes, Angela (Janssen Research and Development) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Hallek, Michael (University of Cologne) ; Universitat Autònoma de Barcelona
Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). [...]
2019 - 10.1016/j.clml.2019.07.004
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 11 (november 2019) , p. 715-722.e6  
8.
11 p, 1.4 MB Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia / Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center) ; Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary) ; Robak, Tadeusz (Medical University of Lodz) ; Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda) ; Bairey, Osnat (Department of Hematology. Rabin Medical Center) ; Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente) ; Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital) ; Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University) ; McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department) ; Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology) ; Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company) ; Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ; Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ; Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center) ; Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele) ; Universitat Autònoma de Barcelona
2022 - 10.1182/bloodadvances.2021006434
Blood advances, Vol. 6 Núm. 11 (june 2022) , p. 3440-3450  
9.
12 p, 1.8 MB Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study / Burger, Jan A. (University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Barr, Paul M. (Wilmot Cancer Institute, University of Rochester Medical Center) ; Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital) ; Owen, Carolyn (University of Calgary. Tom Baker Cancer Centre) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ; Bairey, Osnat (Tel Aviv University. Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine) ; Hillmen, Peter (University of Leeds. The Leeds Teaching Hospitals, St. James Institute of Oncology) ; Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Center) ; Devereux, Stephen (NHS Foundation Trust. Kings College Hospital) ; Grosicki, Sebastian (Silesiam Medical University. Department of Hematology and Cancer Prevention) ; McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; Simpson, David (North Shore Hospital) ; Offner, Fritz (Universitair Ziekenhuis Gent) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Dai, Sandra (Pharmacyclics LLC, an AbbVie Company) ; Lal, Indu (Pharmacyclics LLC, an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company) ; Kipps, Thomas J. (UCSD Moores Cancer Center) ; Universitat Autònoma de Barcelona
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0. [...]
2019 - 10.1038/s41375-019-0602-x
Leukemia, Vol. 34 (october 2019) , p. 787-798  
10.
11 p, 1.8 MB Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma / Munir, Talha (St. James's Hospital ( Dublín, Irlanda)) ; Brown, J. R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ; Barrientos, Jacqueline C. (Northwell Health Cancer Institute (Estats Units d'Amèrica)) ; Barr, Paul M (Wilmot Cancer Institute. University of Rochester Medical Center) ; Reddy, N. M. (Vanderbilt-Ingram Cancer Center) ; Coutre, Steven E. (Stanford Cancer Center. Stanford University School of Medicine) ; Tam, C. S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ; Mulligan, S. P. (Royal North Shore Hospital) ; Jaeger, Ulrich (Division of Hematology and Hemostaseology. Medical University of Vienna) ; Kipps, T. J. (UCSD Moores Cancer Center) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Montillo, M. (Niguarda Ca' Granda Hospital) ; Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Byrd, J. C. (The Ohio State University Comprehensive Cancer Center) ; Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ; Dai, Sandra (Pharmacyclics LLC. an AbbVie Company) ; Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ; Woyach, J. A. (The Ohio State University Comprehensive Cancer Center) ; Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363  

Vegeu també: autors amb noms similars
3 Hillmen, P.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.